Clinical stage medical sensor company Lifecare ASA (Euronext Growth Oslo:LIFE) on Wednesday announced positive results from nine weeks of longevity trial for its Sencell continuous glucose monitor (CGM).

The sensor, implanted in a dog named Elli, has successfully operated for over two months and continues to collect data.

The primary goal of the trial is to assess the sensor's long-term operational lifetime and biocompatibility. Elli, the first patient, is in good health and shows no signs of discomfort from the implant.

Lifecare's CEO, Joacim Holter, emphasised the sensor's impressive longevity compared to existing CGM systems on the market. The company is now preparing to enrol additional patients in the study to further validate the sensor's performance and gather more data on glucose readings in both healthy and diabetic dogs.

Lifecare Veterinary's managing director, Jo Amundstad, said that the company is in discussions with regulatory authorities to extend the implant period to 24 weeks or longer. This will allow for further evaluation of the sensor's long-term impact on tissues.